Skip to main content
SpringerLink
Log in

EGFR and Cytoplasmic Kinase Src Targeting in Pancreatic Cancer

  • Chapter
  • First Online:
Role of Tyrosine Kinases in Gastrointestinal Malignancies

  • 276 Accesses

Abstract

Pancreatic cancer (PC) is one of the most devastating malignancies in the world and the fourth leading cause of fatalities associated with cancer in the United States. PC has an extremely poor prognosis and a 5-year survival rate ranging between 1% and 5%. In emerging PC treatment, tyrosine kinases and its inhibitors signify a new generation of therapeutic drugs that specifically target tumor pathways that are associated with tumorigenesis such as cell cycle mechanism, signal transduction, apoptosis, and angiogenesis. Tyrosine kinases such as EGF and Src kinases were specifically used to target PC progression and metastasis. In this chapter, we discuss the EGFR and Src role in progression PC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30

    Article  Google Scholar 

  2. Casalini P et al (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200(3):343–350

    Article  CAS  Google Scholar 

  3. Alexandrov LB et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415

    Article  CAS  Google Scholar 

  4. Neoptolemos JP et al (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234(6):758

    Article  CAS  Google Scholar 

  5. Inoue S, Tezel E, Nakao A (2001) Molecular diagnosis of pancreatic cancer. Hepato-Gastroenterology 48(40):933–938

    CAS  PubMed  Google Scholar 

  6. Dongbin L et al (2010) Intraductal papillary mucinous neoplasms of the pancreas: diagnosis and management. Eur J Gastroenterol Hepatol 22(9):1029–1038

    Article  Google Scholar 

  7. Hingorani SR et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4(6):437–450

    Article  CAS  Google Scholar 

  8. Handra-Luca A et al (2014) EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins. J Clin Pathol 67(4):295–300

    Article  Google Scholar 

  9. Smit VT et al (1988) KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16(16):7773–7782

    Article  CAS  Google Scholar 

  10. Brennan PJ et al (2002) HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene 21(2):328

    Article  CAS  Google Scholar 

  11. Seshacharyulu P et al (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):15–31

    Article  CAS  Google Scholar 

  12. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967–974

    Article  CAS  Google Scholar 

  13. De Luca A et al (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214(3):559–567

    Article  Google Scholar 

  14. Day JD et al (1996) Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 27(2):119–124

    Article  CAS  Google Scholar 

  15. Jhappan C et al (1990) TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61(6):1137–1146

    Article  CAS  Google Scholar 

  16. Uegaki K et al (1997) Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 17(5B):3841–3847

    CAS  PubMed  Google Scholar 

  17. Bloomston M et al (2006) Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg 23(1–2):74–79

    Article  CAS  Google Scholar 

  18. Lei S et al (1995) Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Gastrointest Cancer 17(1):15–21

    CAS  Google Scholar 

  19. Komoto M et al (2009) HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 100(7):1243–1247

    Article  CAS  Google Scholar 

  20. Ocana A et al (2012) HER3 overexpression and survival in solid tumors: a meta-analysis. JNCI: J Natl Cancer Inst 105(4):266–273

    Article  Google Scholar 

  21. Graber HU et al (1999) ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. Int J Cancer 84(1):24–27

    Article  CAS  Google Scholar 

  22. Thybusch-Bernhardt A, Beckmann S, Juhl H (2001) Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. Int J Surg Investig 2(5):393–400

    CAS  PubMed  Google Scholar 

  23. Cook N, Frese K, Moore M (2014) Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. Gastrointest Cancer: Targets Ther 4:23–37

    Google Scholar 

  24. Korc Ma et al (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Investig 90(4):1352

    Article  CAS  Google Scholar 

  25. Bromann PA, Korkaya H, Courtneidge SA (2004) The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23(48):7957–7968

    Article  CAS  Google Scholar 

  26. Ishizawar R, Parsons SJ (2004) c-Src and cooperating partners in human cancer. Cancer Cell 6(3):209–214

    Article  CAS  Google Scholar 

  27. Nagaraj NS, Washington MK, Merchant NB (2011) Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 17(3):483–493

    Article  CAS  Google Scholar 

  28. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369–385 Elsevier

    Article  CAS  Google Scholar 

  29. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19(56):6550

    Article  CAS  Google Scholar 

  30. Olayioye MA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159–3167

    Article  CAS  Google Scholar 

  31. Boonstra J et al (1995) The epidermal growth factor. Cell Biol Int 19(5):413–430

    Article  CAS  Google Scholar 

  32. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14):2787–2799

    Article  CAS  Google Scholar 

  33. Tzeng C-WD et al (2007) Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol 14(7):2150–2158

    Article  Google Scholar 

  34. Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966

    Article  CAS  Google Scholar 

  35. Jaganathan S, Yue P, Turkson J (2010) Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther 333(2):373–381

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bioscience and Biotechnology, Banasthali University, Banasthali, Rajasthan, India

    Vidya Mukhund & Afroz Alam

  2. Department of Hematology and Medical Oncology, School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA, USA

    Ganji Purnachandra Nagaraju

Authors
  1. Vidya Mukhund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Afroz Alam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ganji Purnachandra Nagaraju
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ganji Purnachandra Nagaraju .

Editor information

Editors and Affiliations

  1. Department of Hematology and Medical Oncology, School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA, USA

    Ganji Purnachandra Nagaraju

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mukhund, V., Alam, A., Nagaraju, G.P. (2018). EGFR and Cytoplasmic Kinase Src Targeting in Pancreatic Cancer. In: Nagaraju, G. (eds) Role of Tyrosine Kinases in Gastrointestinal Malignancies. Springer, Singapore. https://doi.org/10.1007/978-981-13-1486-5_8

Download citation

Publish with us

Policies and ethics

Search

Navigation